Aeglea BioTherapeutics terminates CEO & GC; CFO Alspaugh appointed President

Spyre Therapeutics, Inc.

President/CEO Jeffrey Goldberg and General Counsel Jim Kastenmayer terminated effective May 16, 2023.
Additional severance: $50k to Goldberg, ~$34k to Kastenmayer; Kastenmayer retained as consultant for strategic alternatives.
CFO Jonathan Alspaugh appointed President and principal executive officer.
Retention bonus for Alspaugh up to $222,500 plus performance-based cash payment estimated ~$250k linked to strategic alternatives outcome.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey Goldberg

President and Chief Executive Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-05-16
Successor: Jonathan Alspaugh
Filed: May 19, 2023, 7:59 PM ET

Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.

Role change

Jonathan Alspaugh

President

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-05-16
Filed: May 19, 2023, 7:59 PM ET

In connection with Mr. Goldberg’s departure, the Board appointed Mr. Jonathan Alspaugh, the Company’s Chief Financial Officer, as the Company’s President and principal executive officer.

Departed

Jim Kastenmayer

General Counsel

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-05-16
Filed: May 19, 2023, 7:59 PM ET

Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Goldberg was terminated as President and Chief Executive Officer at Spyre Therapeutics, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Alspaugh was appointed as President at Spyre Therapeutics, Inc..

Action: appointed
Role: President

Exact text from the filing

In connection with Mr. Goldberg’s departure, the Board appointed Mr. Jonathan Alspaugh, the Company’s Chief Financial Officer, as the Company’s President and principal executive officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Kastenmayer was terminated as General Counsel at Spyre Therapeutics, Inc..

Action: terminated
Role: General Counsel

Exact text from the filing

Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-149301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.